Clinical trials: Tissue Plasminogen Activator
Cerebrovascular Accident
Rt-PA in the Treatment of Acute Ischemic Stroke
To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to…
- Trial name
- NCT00153036
- Where
- 142 sites in Austria, Belgium and 17 more
- Volunteers
- 821 people
- Sponsor
- Boehringer Ingelheim
Stroke, Acute
THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA
The purpose of this study is to test the experimental drug "THR-18" given together with the drug "tissue plasminogen activator" for the treatment of stroke. Tissue plasminogen activator is also called "tPA".
- Trial name
- NCT01957774
- Testing
- THR-18
- Where
- Ukraine
- Volunteers
- 30 people
- Sponsor
- D-Pharm Ltd.
Acute Ischemic Stroke
Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke
This is a randomized, placebo controlled, double-blind phase 3 clinical study to evaluate the efficacy and safety of transcranial ultrasound (TUS) using the Sonolysis Headframe as an adjunctive therapy to intravenous (IV) tissue…
- Trial name
- TRUST (NCT03519737)
- Testing
- tPA in combination with the Sonolysis Headframe (TUS)
- Where
- 2 sites in United States
- Volunteers
- 596 people
- Sponsor
- Cerevast Medical, Inc.
Stroke
Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.
- Trial name
- CERE-LYSE-1 (NCT00840671)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 15 sites in Austria, Croatia and 3 more
- Volunteers
- 119 people
- Sponsor
- Ever Neuro Pharma GmbH
Stroke
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment within 4.5 hours of symptom…
- Trial name
- NCT05401149
- Testing
- rt-PA
- Where
- China
- Volunteers
- 3,058 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke, rhTNK-tPA
Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke
This is a multicenter, prospective, non-randomized, post-marketing safety surveillance cohort study with rt-PA (Actilyse®) as the control.
- Trial name
- NCT07519889
- Testing
- rhTNK-tPA, rt-PA
- Volunteers
- 4,500 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Ischemic Stroke
Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study was to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of multiple ascending intravenous doses of 3K3A-APC, a Recombinant Variant of Human activated protein C (APC), in in the…
- Trial name
- RHAPSODY (NCT02222714)
- Testing
- 3K3A-APC
- Where
- 15 sites in United States
- Volunteers
- 110 people
- Sponsor
- ZZ Biotech, LLC
Myocardial Infarction
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and half dose tenecteplase combined with…
- Trial name
- ASSENT 3 (NCT02181985)
- Testing
- Full dose TNK-tPA, Half dose TNK-tPA, Heparin
- Volunteers
- 5,989 people
- Sponsor
- Boehringer Ingelheim
Stroke, Acute, Stroke, Ischemic
Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial
The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation…
- Conditions
- Stroke, Acute, Stroke, Ischemic, Infarction, Middle Cerebral Artery, Strokes Thrombotic
- Trial name
- MEDIS (NCT03098732)
- Testing
- Magnetically Enhanced Diffusion (MED)
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Pulse Therapeutics
Catheter Occlusion, Thrombosis
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.
- Trial name
- READY1 (NCT03594175)
- Testing
- CUSA-081, Alteplase
- Where
- 77 sites in United States, Argentina and 5 more
- Volunteers
- 462 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Stroke
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA)…
- Trial name
- NCT00412867
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Tanabe Pharma Corporation
Ischemic Stroke
A Safety Evaluation of the Use of Magnetic-guided Iron Particles
This study is a prospective trial wherein each included subject will receive the experimental magnetically enhanced diffusion therapy.
- Trial name
- NCT01519076
- Testing
- Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)
- Where
- 2 sites in Australia
- Volunteers
- 7 people
- Sponsor
- Pulse Therapeutics
Healthy
A Study in Healthy Men to Compare 2 Different Formulations of Alteplase
To establish the bioequivalence of alteplase derived from two different manufacturing processes.
- Trial name
- NCT04419493
- Testing
- Alteplase (from modified manufacturing process), Alteplase (from current manufacturing process), Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
Primary objective: to evaluate the procoagulant effect of TNK-tPA compared to rt-PA and streptokinase, administered to patients with AMI, by measuring the concentration of TAT at 2 hours after the start of treatment versus…
- Trial name
- NCT02182011
- Testing
- Tenecteplase, Alteplase, Streptokinase
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)
This will be a randomized, double-blind, placebo-controlled, multi-center, multi-national, escalating dose, pilot study comparing two doses of THR-18 to placebo when administered to patients suffering acute ischemic stroke and…
- Trial name
- NCT01253512
- Testing
- THR-18
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Thrombotech Ltd.
Acute Respiratory Distress Syndrome
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study.
- Trial name
- TRISTARDS (NCT04640194)
- Testing
- Standard of care, Alteplase low dose, Alteplase high dose
- Where
- 37 sites in Austria, Belgium and 11 more
- Volunteers
- 104 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with…
- Trial name
- RHAPSODY-2 (NCT05484154)
- Testing
- 3K3A-APC
- Sponsor
- ZZ Biotech, LLC
Ischemic Stroke, Atrial Fibrillation
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)
The proposed study will validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes as listed below: 1.
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events
- Trial name
- BASE (NCT02014896)
- Testing
- Biomarker blood draw
- Where
- 22 sites in United States
- Volunteers
- 1,750 people
- Sponsor
- Ischemia Care LLC
Catheter Obstruction, Vascular Access Devices
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion
This is a multicentre, open-label, randomised, phase III study designed to evaluate the efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD
- Trial name
- NCT01958164
- Testing
- Actilyse, Saline solution
- Where
- 5 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
Feasibility and Safety of NeuroFlo in Stroke Patients Receiving Tissue Plasminogen Activator
To assess the safety and feasibility of using the NeuroFlo catheter to treat acute ischemic stroke patients following administration of intravenous tPA.
- Trial name
- FASTFlo tPA (NCT01006993)
- Testing
- NeuroFlo catheter
- Where
- 4 sites in Canada, Germany
- Volunteers
- 22 people
- Sponsor
- CoAxia